0001193125-26-103121
SEC filingMBX Biosciences, Inc. reported a net loss of $87.0 million for the fiscal year ended December 31, 2025, compared to a net loss of $61.9 million in the prior year. The increased loss was driven by a significant rise in operating expenses, which totaled $98.1 million, up from $68.2 million in 2024. Research and development expenses increased to $79.2 million, primarily due to advancing the Phase 2 clinical trial and manufacturing for canvuparatide, initiating the Phase 1 trial for MBX 4291, and pipeline development. General and administrative expenses rose to $18.9 million, supporting infrastructure growth. The company generated $11.1 million in interest and other income from its cash and marketable securities. As of December 31, 2025, MBX had $373.7 million in cash, cash equivalents, and marketable securities, which it believes will fund operations into 2029. The company remains a clinical-stage biopharmaceutical company with no product revenue, focusing on developing peptide therapies for endocrine and metabolic disorders.
MBX Biosciences, Inc. reported a net loss of $87.0 million for the fiscal year ended December 31, 2025, a significant increase from the $61.9 million net loss in 2024. This deterioration was primarily due to a substantial rise in operating expenses, which totaled $98.1 million, up 44% from $68.2 million in the prior year. The loss from operations was $98.1 million. The company partially offset these losses with $11.1 million in interest and other income, net, generated from its cash, cash equivalents, and marketable securities. The net loss per common share, basic and diluted, was $2.00, based on a weighted average of 36.5 million common shares outstanding. The company's accumulated deficit grew to $224.5 million as of December 31, 2025, from $137.5 million a year earlier, reflecting its ongoing investment in research and development without generating product revenue.
The company is a clinical-stage biopharmaceutical company and has not generated any revenue from product sales. Its operations are entirely focused on the discovery, development, and commercialization of novel precision peptide therapies. The financial results are driven by research and development expenditures and general administrative costs, with no revenue streams from commercialized products. The document does not disclose any segment or geographic revenue breakdown, as the business is pre-revenue.
As a pre-revenue company, MBX Biosciences does not report gross profit or gross margin. The company's operating loss of $98.1 million reflects its investment in research and development and general administrative functions. Operating expenses were comprised of $79.2 million in research and development costs and $18.9 million in general and administrative expenses. The increase in R&D expenses of $21.7 million year-over-year was driven by clinical trial activities for canvuparatide and MBX 4291, a milestone payment to IURTC, and pipeline development. The increase in G&A expenses of $8.1 million was due to higher professional fees and personnel-related costs to support operational growth.
Net cash used in operating activities was $79.9 million for the year ended December 31, 2025, primarily due to the net loss of $87.0 million, partially offset by non-cash charges and changes in operating assets and liabilities. Net cash used in investing activities was $83.7 million, relating to purchases of marketable securities and property and equipment, offset by maturities and redemptions of marketable securities. Net cash provided by financing activities was $189.6 million, primarily from a public offering in September 2025. This resulted in a net increase in cash and cash equivalents of $25.9 million. The balance sheet as of December 31, 2025, shows total assets of $385.1 million, including $75.3 million in cash and cash equivalents and $298.4 million in marketable securities. Total liabilities were $15.9 million, resulting in total stockholders' equity of $369.2 million. The company believes its existing cash, cash equivalents, and marketable securities of $373.7 million will be sufficient to fund its operating expenses and capital expenditure requirements into 2029.
The company's future success depends on the successful development, regulatory approval, and commercialization of its product candidates, including canvuparatide, imapextide, and MBX 4291. Management anticipates expenses and operating losses will increase substantially as it advances clinical trials, seeks regulatory approvals, establishes manufacturing capabilities, and potentially builds commercial infrastructure. The company expects to need substantial additional funding in the future and plans to finance operations through equity offerings, debt financings, collaborations, or other strategic transactions. Key risk factors highlighted include the uncertainty of clinical development, regulatory challenges, competition, intellectual property protection, and the need for additional capital. The company has not provided specific financial guidance for future periods.